Carisma Therapeutics (CARM) Stock Price, News & Analysis

Company Overview

Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

Key Stats

• Today's Range: $0.38 to $0.41
• 50-Day Range: $0.39 to $1.11
• 52-Week Range: $0.38 to $3.16
• Volume: 439,958 shs
• Average Volume: 339,554 shs
• Market Capitalization: $16.66 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.94
• Consensus Rating: Hold

Carisma Therapeutics Stock Analysis - MarketRank™

Carisma Therapeutics scored higher than 68% of companies evaluated by MarketBeat, and ranked 330th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Hold

Consensus Rating

Carisma Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 1 buy rating, 5 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Carisma Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Carisma Therapeutics are expected to grow in the coming year, from ($1.32) to ($1.26) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Carisma Therapeutics is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Carisma Therapeutics is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Carisma Therapeutics has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.55% of the float of Carisma Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Carisma Therapeutics has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Carisma Therapeutics has recently decreased by 0.79%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Carisma Therapeutics does not currently pay a dividend.

Dividend Growth

Carisma Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.55% of the float of Carisma Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Carisma Therapeutics has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Carisma Therapeutics has recently decreased by 0.79%, indicating that investor sentiment is improving.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Carisma Therapeutics this week, compared to 1 article on an average week.

Search Interest

Only 4 people have searched for CARM on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

MarketBeat Follows

4 people have added Carisma Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Carisma Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

12.57% of the stock of Carisma Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

44.27% of the stock of Carisma Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CARM Stock Analysis - Frequently Asked Questions

How have CARM shares performed this year?

Carisma Therapeutics' stock was trading at $2.93 on January 1st, 2024. Since then, CARM stock has decreased by 86.4% and is now trading at $0.3990.
View the best growth stocks for 2024 here.

How were Carisma Therapeutics' earnings last quarter?

Carisma Therapeutics, Inc. (NASDAQ:CARM) announced its quarterly earnings data on Thursday, November, 7th. The company reported ($0.31) EPS for the quarter, meeting analysts' consensus estimates of ($0.31). The business had revenue of $3.39 million for the quarter. Carisma Therapeutics had a negative trailing twelve-month return on equity of 957.20% and a negative net margin of 314.78%.

Who are Carisma Therapeutics' major shareholders?

Top institutional investors of Carisma Therapeutics include Barclays PLC (1.32%), Barclays PLC (1.32%), Geode Capital Management LLC (0.62%) and Wexford Capital LP (0.08%).

How do I buy shares of Carisma Therapeutics?

Shares of CARM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Carisma Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Carisma Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), Broadcom (AVGO) and Palo Alto Networks (PANW).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 12/25/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CARM
• CUSIP: N/A
• CIK: 1485003
• Web: N/A
• Phone: 617-444-8550
• Fax: 617-858-0911
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $4.94
• High Stock Price Target: $12.00
• Low Stock Price Target: $0.70
• Potential Upside/Downside: +1,138.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.43
• Research Coverage: 7 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.56)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-86,880,000.00
• Net Margins: -314.78%
• Pretax Margin: -315.75%
• Return on Equity: -957.20%
• Return on Assets: -96.39%

Debt

• Debt-to-Equity Ratio: 1.39
• Current Ratio: 3.23
• Quick Ratio: 3.23

Sales & Book Value

• Annual Sales: $20.27 million
• Price / Sales: 0.82
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.66 per share
• Price / Book: 0.60

Miscellaneous

• Outstanding Shares: 41,750,000
• Free Float: 36,502,000
• Market Cap: $16.66 million
• Optionable: No Data
• Beta: 1.44